期刊文献+

不同剂量甲氨蝶呤联合放疗治疗原发性中枢神经系统淋巴瘤疗效分析 被引量:4

下载PDF
导出
摘要 目的分析不同剂量甲氨蝶呤联合放疗治疗原发性中枢神经系统淋巴瘤的治疗效果。方法选取我院神经科2010-01—2013-12收治42例原发性中枢神经系统淋巴瘤患者作为临床研究对象,随机分为2组,每组21例。A组给予小剂量甲氨蝶呤联合放疗,剂量为1g/m2,B组给予大剂量甲氨蝶呤联合放疗,剂量为3g/m2,对比2组患者的治疗效果与不良反应发生情况。结果 (1)A组患者的完全缓解率为57.14%,B组为23.81%,2组比较差异具有统计学意义(P<0.05);(2)2组患者主要出现了谷丙转氨酶升高以及骨髓抑制等不良反应,2组的谷丙转氨酶升高发生差异无统计学意义(P<0.05);B组的骨髓抑制要明显高于A组,差异有统计学意义(P<0.05);2组患者化疗期间均未出现死亡病例。结论大剂量甲氨蝶呤化疗联合放疗治疗原发性中枢神经系统淋巴瘤效果显著,虽会加重骨髓抑制,但安全性可以保证,值得临床推广。
作者 弋振营
出处 《中国实用神经疾病杂志》 2014年第17期120-121,共2页 Chinese Journal of Practical Nervous Diseases
  • 相关文献

参考文献3

二级参考文献26

  • 1于同刚,戴嘉中,冯晓源.原发性中枢神经系统淋巴瘤的MRI及^1H-MRS特点[J].临床放射学杂志,2005,24(8):668-672. 被引量:64
  • 2李明洙,罗力,高乃康,富春雨,窦长武,王涛,李云霞.原发性颅内淋巴瘤分型及治疗[J].中华神经外科杂志,2006,22(4):259-260. 被引量:30
  • 3杨子江,汪林.原发性中枢神经系统淋巴瘤的MRI[J].中国临床医学影像杂志,2007,18(6):387-389. 被引量:6
  • 4庞青松,王静,王平.原发性中枢神经系统淋巴瘤研究进展[J].中国肿瘤临床,2007,34(15):892-895. 被引量:16
  • 5Mohile NA, Abrey LE. Primary central nervous system lymphoma. Neurol Clin 2007,25(4) :1193-1207.
  • 6Shenkier TN, VossN,ChhanabhaiM, et al. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients. Cancer, 2005, 103 (5) : 1008- 1017.
  • 7Nakamura M, Shimada K, Ishida E, et al. Histopathology, pathogenesis and molecular genetics in primary central nervous system lyinphomas. Histol Histopathol. 2004, 19 ( 1 ):211-219.
  • 8Kuker W, Niagele T, Korfel A, et al. Primary central nervous system lymphomas (PCNSL) : MRI features at presentation in 100 patients. J Neurooncol, 2005,72 (2) : 169-177.
  • 9Buhring U, Herrlinger U, Krings T, et al. MRI features of primary central nervous system lymphomas (PCNSL) at presentation. Neurology,2001,57 (3): 393-396.
  • 10Bessell EM, Hoang-Xuan K, Ferreri AJ, et al. Primary central nervous system lymphoma: biological aspects and controversies in management. Eur J Cancer, 2007, 43 (7): 1141-1152.

共引文献47

同被引文献37

  • 1Ding Y, Xing Z, Liu B, et al. Differentiation of primary central nervous system lymphoma from high - grade glioma and brain metastases using susceptibility -weighted imaging[ J]. Brain Behav,2014,4 (6) : 841 - 849.
  • 2Siegal T. Primary central nervous system lymphoma: current state of anti - CD20 therapy and appraisal of reported re- sponse criteria[ J]. J Clin Neurosci ,2014,21 (5) :709 -715.
  • 3Chamberlain MC. Salvage therapy with bendamustine for methostrexate refractory recurrent primary CNS lymphoma: a retrospective case series [ J ]. J neurooncol, 2014,118 ( 1 ) : 155 - 162.
  • 4Raizer J J, Rademaker A, Evens AM, et al. Pemetrexed in the treatment of relapsed/refractory primary central nervous sys- tem lymphoma [ J]. Cancer,2012,118 ( 15 ) :3743 - 3748.
  • 5Choi MK, Kang ES, Kim DW, et al. Treatment outcome of re- lapsed/refra- ctory primary central nervous system diffuse large B - cell lymphoma : a single - center experience of au- tologous stem cell transplantation[ J]. Int J Hematol,2013,98 ( 3 ) : 346 - 354.
  • 6Welch MR, Sauter CS, Matasar M J, et al. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous systemlymphoma using thiotepa, busulfan and cyclophosphamide [ J ]. Leuk Lymphoma ,2015,56 ( 2 ) : 361 - 367.
  • 7Fen'eft A J, Reni M. Primary central nervous system lympho- ma[J ]. crit Rev Oncol Hemato1,2007,63 ( 3 ) : 257 - 268.
  • 8Deckert M, Engert A, Brtick W, et al. Modem concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma [ J ]. Leukemia, 2011,25 ( 12 ) : 1797 - 1807.
  • 9Batchelor T, Loeffler JS. Primary cnslymphoma [ J ]. J Clin Onco1,2006,24( 8 ) : 1281 - 1288.
  • 10Pels H, Schmidt - Wolf IG, Glasmacher A, et al. Primary central nervous system lymphonla: results of a pilot and phase 1 I study of systemic and intraventrieular chemothera- py with deferred radiotherap [ J ]. J Clin Oneol, 2003,21 ( 24 ) :4489 - 4495.

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部